IMBALANCED MHC CLASS II MOLECULE EXPRESSION AT SURFACE OF MURINE B CELL LYMPHOMAS

BY MAARTEN ZIJLSTRA, WIES L. E. VASMEL, MICHEL VOORMANNS, RUUD E. Y. DE GOEDE, HARRIE J. SCHÖNMAKERS, JOHN NIELAND*, ROSALYN M. SLATER*, AND CORNELIS J. M. MELIEF

From the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, the Laboratory for Experimental and Clinical Immunology of the University of Amsterdam, Amsterdam, The Netherlands; and the *Institute of Human Genetics, Academic Medical Centre, Amsterdam, The Netherlands

The MHC of the mouse (H-2 complex) exerts a marked influence on resistance against murine viral lymphomagenesis (1–7). Resistance genes to various murine leukemia virus (MuLV) isolates have been mapped (1–6) to several regions within the H-2 complex, i.e. the K, I-A, I-E, S, and/or D regions. In one study (8), complementation with respect to resistance between the I-A and I-E regions was observed.

The H-2 influence on susceptibility to MuLV-induced lymphomas is usually compatible with H-2-controlled immunological resistance mechanism(s) directed against MuLV or MuLV cell surface antigens (3, 9–16). H-2-controlled immune mechanisms were shown to operate at the level of antiviral antibodies (11, 14–16), virus-specific proliferating T cells (12), virus-specific cytotoxic T cells (10), or I region–linked inhibition of the outgrowth of preleukemic cells (13).

A second mechanism by which the MHC influences lymphomagenesis in the mouse, besides immune response regulation, is variation in the level of expression of MHC molecules on tumor cells. So far this issue has only been investigated for class I MHC molecules. H-2-linked resistance to radiation leukemia virus infection has been associated (9, 10) with an increased and selective expression of certain class I MHC antigens. Transfection of the AKR K36 cell line, which lacks Kk cell surface expression (17, 18), with a transcriptionally active Kk gene, makes this cell line much less transplantable in syngeneic recipient mice (18), possibly due to enhanced susceptibility to Kk-restricted MuLV-specific cytotoxic T cells (17, 18). Some Moloney MuLV–induced T cell tumors and SJL/J B cell tumors have lost expression of certain class I MHC molecules (19, 20).

Other experimental models also indicate a role for aberrant class I MHC expression in tumorigenesis. Imbalance in the expression of class I H-2 molecules influences the metastatic properties of lung carcinoma (21), sarcoma (22–25) and B16 melanoma cells (26) in mice. The oncogenic potential of adenovirus-
transformed rat cells is correlated with the adenovirus E1A product(s), which influence(s) class I MHC expression (27, 28). Introduction and expression of a transfected class I MHC gene was sufficient to abrogate the oncogenicity of highly tumorigenic adenovirus 12-transformed mouse cells (29).

Previously, we described the induction and phenotypic characteristics of a large number of lymphomas of H-2-congenic C57BL and BALB/c mice that arose spontaneously (6), were induced by milk-transmitted ecotropic MuLV (6), or by neonatal inoculation of cloned MuLV (7, 30). Analysis of class II MHC antigen expression on a series of B10.A(H-2b) lymphomas indicates that (a) most primary B cell lymphomas express high levels of both I-A and I-E antigens at the cell surface, (b) some B cell lymphomas have an I-A-, I-E+ phenotype, (c) the loss of cell surface I-A expression can be the result of either a diminished Aα or Aβ mRNA expression, and (d) one of the I-A-, I-E+ B cell tumors contains a (11; 17) translocation with a breakpoint on chromosome 17 within or very close to the H-2 complex. To our knowledge this is the first detailed description of imbalanced class II MHC expression in an animal tumor model.

Materials and Methods

Tumor Induction. The development of the C57BL/10ScSn [B10(H-2b)] and B10.A(SJL) [B10.A(H-2b)] sublines, virus-negative or with milk-transmitted B-epitropic MuLV, was described in detail before (6). The induction of lymphomas by neonatal inoculation with cloned MuLV isolates has been described (7, 30). B10.A mice were purchased from Olac Ltd., Bicester, United Kingdom. For evaluation of tumor incidence, animals were observed three times a week for signs of tumor development or general illness. Moribund mice were killed for autopsy and viable cell suspensions from lymphomas were frozen with a programmed cooling device and cryopreserved in liquid nitrogen in 10% DMSO as described (6). In addition, tumor tissues were directly frozen in liquid nitrogen for DNA and RNA analyses.

Tumor Cell Characterization. Haematologic neoplasias were classified morphologically according to the Pattengale-Taylor classification (31). The characterization of the cell surface markers expressed by the lymphoma cells was performed by flow cytofluorometry on a Coulter Epics-C. Data were collected from 5,000 viable cells by using logarithmic amplification of signals from the photomultiplier tubes and plotted on a linear fluorescence scale.

Antibodies. The rat mAb directed against Thy-1 (59AD2.2) (32), B220 (RA3-2C2) (33), Lyt-1 (55-7.3) (32), Lyt-2 (53-6.7) (32), T200 (30G12) (32), and mac-1 (M1/70.15) (34) were used at 1:1 dilutions of tissue culture supernatant containing mAb. The characteristics of the mAb directed against the I-A, I-E, and Kk antigens used in this study are summarized in Table I. The haplotype specificity of anti-MHC mAb was confirmed by their reaction with spleen cells of a panel of recombinant C57BL mice. Anti-MHC mAb were used at 1:100 dilutions of ascites containing mAb. As second antibodies in the flow cytofluorometry experiments, the following fluorescein-labeled antisera were used: goat anti–mouse Ig (1:20; Central Laboratory of the Netherlands Red Cross Blood Transfusion Service) and rabbit anti–rat Ig (1:50; Cappel Laboratories, Cochranville, PA).

DNA Analysis. Isolation of cellular DNA was performed as described (40). DNA samples (15 μg) were digested under conditions recommended by the suppliers (Boehringer-Mannheim Diagnostics, Inc., Mannheim, Federal Republic of Germany). Gel electrophoresis, transfer to nitrocellulose filter and hybridization to 32P-labeled probes was carried out as described (41). As molecular weight markers, Hind III-digested phage λ DNA was used. Finally, filters were washed in 0.1× SSC plus 0.1% SDS for 15 min at 60°C (class II MHC–specific probes) or 65°C (AKR [AKR leukemia virus]-LTR probe), dried, and autoradiographed with Kodak X-Omat R film and intensifying screens.

RNA Analysis. For RNA isolation, frozen tissues were homogenized with a polytron
TABLE I

Characteristics of Mouse Anti-MHC mAb

| Hybrid cell line     | Ig class | Molecule detected | Haplotype reactivity | Reference |
|----------------------|----------|-------------------|----------------------|-----------|
| B17-263R1            | IgM      | I-A               | b, d, j, p, g        | 35        |
| B17-123R2            | IgM      | I-A               | b, d, j, p, g, r, (s)* | 35        |
| 17/227R7             | IgG2a    | I-A               | b, d, i, k, (u)      | 35        |
| 25-9-17S             | IgG2a    | I-A               | b, d, (p), (q)       | 36        |
| 34-5-3S              | IgG2a    | I-A               | b, d, (p), (q)       | 37        |
| 28-16-8S             | IgG2a    | I-A               | b                    | 36        |
| K25-8-7              | IgG2a    | I-A               | b, f, k, r, s, q     | G. Hämmerling, unpublished data |
| 11-5.2*              | IgG2b    | I-A               | k                    | 38        |
| 11-3.25*             | IgG2b    | I-A               | f, k, r, s           | 38        |
| 13/18                | IgG2a    | I-E               | d, j, k, p, r, u, v  | 35        |
| 14-4.4S              | IgG2a    | I-E               | d, k, p, r           | 39        |
| 11-4.11*             | IgG2a    | H-2K              | h, r, p, q           | 38        |

* Weak crossreactivity.

© Obtained from Becton Dickinson and Co. (Mechelen, Belgium).

(30 s, full speed) at 0°C in 3 M LiCl, 6 M urea, and maintained overnight at 4°C. After centrifugation at 15,000 g for 1 h, the pellet was dissolved in 10 mM Tris-HCl, pH 7.5, and 1 mM EDTA. Subsequently the RNA was deproteinized by phenol and subsequent chloroform/isooamyl alcohol (24:1) extraction, and precipitated with ethanol. For dot-blot analysis, RNA was dissolved in 10 mM Tris-HCl (pH 7.5), 1 mM EDTA, and applied to nitrocellulose filters as described (42). Northern blot analysis of RNA with formaldehyde-treated 1.0% agarose gels was performed as described (27). Hybridization to 32P-labeled probes was carried out as described (41). Finally, filters were washed in 0.1x SSC plus 0.1% SDS at 60°C for 15 min, dried, and autoradiographed with Kodak X-Omat R film and intensifying screens. To remove radioactive label, filters were washed at 68°C for 2 h in H2O/formaldehyde 1:1 (vol/vol) and preexposed to x-ray film to ensure that no residual label was left.

Hybridization Probes. The hybridization probe specific for the U3-LTR of AKV-MuLV (AKV-LTR) has been described in detail previously (43). The following class II MHC-specific hybridization probes were used: Aα, an Eco RI fragment, containing an almost full-length Aα cDNA inserted into the Eco RI site of pBR322 (44); Aβ, pc1Aβ-1, a 464 bp 3′ cDNA probe encompassing the transmembrane, intracytoplasmic, and 3′ untranslated region of Aβ4, inserted in the Pst 1 site of pBR322 (45); Ea, an ~700 bp cDNA clone of Ea4 inserted into the Pst 1 site of pBR322 (R. N. Germain, unpublished data); Eβ, an ~500 bp cDNA clone containing the β2, transmembrane, and cytoplasmic region of Eβ4 subcloned into pUC8 (R. N. Germain, unpublished data).

Cytogenetic Studies. Tumor-bearing mice were injected 20 min before section with 10 μg demecolcine (Sigma Chemical Co., St. Louis, MO) dissolved in HBSS. Tumor-affected organs were removed, mechanically dissociated through a fine metal gauze, and the resulting cells were centrifuged for 10 min at 1,200 rpm. The cell pellet was resuspended in 0.075 M KCl at 37°C and incubated at 37°C for 25 min. Before centrifugation (10 min at 1,200 rpm) a few drops of freshly prepared fixative (methanol/glacial acetic acid, 3:1) was added and mixed thoroughly. After centrifugation, the cell pellet was gently resuspended in fresh fixative, and any remaining pieces of tissue or cell clumps were discarded. The cell suspension was allowed to stand at room temperature for 25 min, centrifuged, and resuspended in fresh fixative. This last step was repeated until a clear cell suspension was obtained. Air-dried preparations were made on alcohol-cleaned glass slides.

Chromosome preparations were stored for ~14 d at room temperature before being stained by a G-banding technique based on that of Herbst et al. (46). Basically, slides were
TABLE II

Characteristics of Two Primary B10.A B Cell Lymphomas with Strongly Reduced I-A Cell Surface Expression

| Primary tumor | Strain | Sex | Age (mo) | Inducing agent | Mouse lymphocyte differentiation markers | Class II MHC expression | Histology# |
|---------------|--------|-----|----------|----------------|------------------------------------------|-------------------------|------------|
|               |        |     |          |                | T200 Thy Mac-1 B220 slg                  | Control I-A I-E         |            |
| 1189 B10.A    | 9      | 19  |          | Milk-transmitted MuLV | + - - + + 70 | 81 90 60 188 | Immunoblastic |
| 1464 B10.A    | 9      | 29  |          | Spontaneous      | + - - + ± 20 | 50 86 40 192 | Lymphoblastic |
| 12424 B10.A   | d      | 13.5|          | Milk-transmitted MuLV | + - - + ± 30 | 91 86 60 188 | Follicle center cell, large cell type |

* Classification according to Pattengale and Taylor (31).
++, strong expression; ±, weak expression; -, no expression.
* Percentage of cells above channel 30.
* Mean intensity of fluorescence (channel number) of cells above channel 30.
* Representative primary B10.A B cell with a strong I-A/E expression.

Results

Cell-surface I-A/E Expression of Primary B10.A B cell Lymphomas. The cell surface I-A/E expression of 24 primary B10.A (I-A<sup>k</sup>, I-E<sup>k</sup>) B cell tumors was determined by flow cytofluorometry with a panel of nine I-A- and two I-E- reactive mAb (Table I). 3 spontaneous and 19 MuLV-induced B10.A B cell lymphomas expressed both I-A<sup>k</sup> and I-E<sup>k</sup> antigens. In addition, in these 22 tumors, no serological aberrations were observed in their reaction with any of the 11 I-A/E-specific mAb (data not shown).

However, two primary B10.A B cell lymphomas were observed that displayed strong I-E<sup>k</sup> but only minimal I-A<sup>k</sup> expression at the tumor cell surface (Table II). Tumor 1464 arose spontaneously and tumor 1189 was induced by a milk-transmitted B-ecotropic MuLV (6) (Table II). Both tumors had a T200<sup>+</sup>, B220<sup>+</sup>, slg<sup>+</sup>, Thy-1<sup>-</sup>, mac-1<sup>-</sup> phenotype (Table II). Strikingly, both primary I-A<sup>-</sup>, I-E<sup>+</sup> tumors were localized exclusively in the greatly enlarged mesenteric lymph node.

Stability of I-A<sup>-</sup>, I-E<sup>+</sup> Tumor Phenotype upon Transplantation. Both B10.A I-A<sup>-</sup>, I-E<sup>+</sup> tumors were transplanted into several syngeneic recipient mice, which developed lymphomas in 4–8 wk (Table III). The transplanted I-A<sup>-</sup>, I-E<sup>+</sup> tumors were much more aggressive than the primary I-A<sup>-</sup>, I-E<sup>+</sup> tumors, as indicated by extensive tumor cell infiltrations into spleen, mesenteric and other lymph nodes, kidney, and liver. Tumor cells from different organs of individual transplants strongly expressed I-E<sup>k</sup>, as determined by their reaction with the mAb 13-18.
TABLE III

Relationship Between Transplantability of Primary B10.A B Cell Lymphomas and I-A/E Expression of Primary and Transplanted Tumors

| Tumor                                | I-A/E phenotype of primary tumor | Animals with tumor after transplantation* | Latency (d) | I-A/E phenotype of transplants | Transplants tested (n) |
|---------------------------------------|----------------------------------|------------------------------------------|-------------|---------------------------------|-----------------------|
| Spontaneous tumors                    |                                  |                                          |             |                                 |                       |
| 1252                                 | I-A<+)E<+)                         | 0/3                                      | >100        |                                 |                       |
| 1265                                 | NT†                              | 0/3                                      | >100        |                                 |                       |
| 1285                                 | NT                               | 4/5                                      | 50.2 ± 10.2 | I-A<+)E<+)                       | 2                     |
| 1359                                 | I-A<+)E<+)                        | 0/6                                      | >100        |                                 |                       |
| 1464                                 | I-A<+)E<+)                        | 0/6                                      | >100        |                                 |                       |
| Milk-transmitted MuLV-induced tumors  |                                  |                                          |             |                                 |                       |
| 1096                                 | NT                               | 1/9                                      | 61          | I-A<+)E<+)                       | 1                     |
| 1099                                 | I-A<+)E<+)                        | 9/9                                      | 19.6 ± 1.4  | I-A<+)E<+)                       | 2                     |
| 1224                                 | I-A<+)E<+)                        | 1/10                                     | 96          | I-A<+)E<+)                       | 1                     |
| 1189                                 | I-A<+)E<+)                        | 2/2                                      | 36, 40      | I-A<+)E<+)                       | 2                     |

* Transplantation was performed by i.p. inoculation of 5–20 × 10⁶ live primary tumor cells in syngeneic recipients.
† +, strong expression (positive cells >50 channels above background fluorescence with FITC-labelled goat anti-mouse Ig); (+), weak expression (positive cells 10–50 channels above background fluorescence); −, no expression (positive cells <10 channels above background fluorescence).
‡ NT, not tested because no more live cells were available.
§ Mean ± SD.

FIGURE 1. Expression of H-2 antigens by transplant 2 of B10.A tumor 1464 as determined by flow cytofluorometry with mAb directed against I-A<+> (17/227R7), I-E<+> (13-18), and K<+> (11-4.1) antigens. The primary I-A<−>, I-E<+> B10.A tumors 1464 and 1189, and individual transplants of these tumors showed similar fluorescence patterns (data not shown). (Fig. 1) and 14-4-4S (data not shown). With mAb 17/227R7 (Fig. 1) and three other I-A<+> reactive mAb (data not shown), only minimal fluorescence above background was seen. With seven mAb that do not react with I-A<+> but detect I-A molecules from a wide spectrum of H-2 alleles (Table I), no reaction was observed. Comparable results were obtained with the primary tumor 1464 and the primary and individual transplants of tumor 1189 (Tables II and III). Both the primary (data not shown) and transplanted (Fig. 1) I-A<−>, I-E<+> tumors expressed the K<+> molecule on the cell surface (Fig. 1). These findings make it unlikely that the minimal cell surface detection of I-A<+> antigens is caused by either (a) a mix-up of tumor cells, or (b) a mutation in the I-A<+> molecule.
Relationship between Transplantability of Primary B10.A B Cell Lymphomas and I-A/E Expression of Primary and Transplanted Tumors. To evaluate the biological significance of the I-A\(^-\), I-E\(^+\) phenotype, we determined the I-A/E phenotype and transplantability of a total of nine B10.A primary B cell tumors, namely seven random B10.A B cell tumors and the two I-A\(^-\), I-E\(^+\) tumors (Table III). Four of these primary tumors expressed both I-A and I-E antigens, while the other three were not characterized because no viable primary cells were available. Two out of three of these primary tumors most likely had an I-A\(^+\), I-E\(^+\) phenotype, however, because (a) they were transplantable and the transplants had an I-A\(^+\), I-E\(^+\) phenotype (Table III); and (b) all other transplantable tumors also retained the I-A\(^+\), I-E\(^+\) phenotype of the primary tumor (Table III). Of the seven random B10.A B cell tumors, two were readily transplantable, two transplantable in only a small minority of recipient mice, and three not transplantable in the number of animals tested (Table III). This frequency of takes is comparable to that of I-A\(^+\) B10 B cell tumors (three out of eight transplantable; data not shown), but differs significantly from the uniformly excellent transplantability of the T cell tumors from the same experimental model (6, 7), i.e. all 13 B10.A, and all 4 B10 T cell tumors were readily transplantable (data not shown).

Expression of Class II MHC-specific mRNA in I-A\(^-\), I-E\(^+\) Tumors. To further document the minimal cell surface I-A expression of the two I-A\(^-\), I-E\(^+\) tumors, and to explore its mechanism(s), we examined the expression of class II MHC-specific mRNA. The results of Northern blot analysis with total cellular RNA are shown in Fig. 2. Two individual transplants of tumor 1189 (lanes 2 and 3) possess a greatly reduced expression of the 1.4 kb A\(\beta\) mRNA (Fig. 2), but a strong expression of both the A\(\alpha\) (Fig. 2, lanes 2 and 3), E\(\beta\) (Fig. 2, lanes 2 and 3), and E\(\alpha\) mRNA (data not shown). Three individual transplants of tumor 1464 (Fig. 2, lanes 4–6) express a low level of the 1.4 kb A\(\alpha\) mRNA (Fig. 2, lanes 4–6) but high levels of A\(\beta\) (Fig. 2, lanes 4–6), E\(\beta\) (Fig. 2, lanes 4–6) and E\(\alpha\) mRNA (data not shown). 3 primary B10.A B cell lymphomas (Fig. 2, lanes 7–9) and 11 other primary or transplanted B cell lymphomas (data not shown) with a normal I-A\(^+\), I-E\(^+\) cell surface expression show a comparably high level of expression of the A\(\alpha\), A\(\beta\), and E\(\beta\) mRNAs. Comparable results were obtained in dot-blot analyses (data not shown).

DNA Analysis of I-A\(^-\), I-E\(^+\) Tumors. In Southern blot analyses with Eco R1\(\rightarrow\), Kpn I\(\rightarrow\), Eco RV\(\rightarrow\), and Hind III-digested DNA, no additional restriction enzyme fragments hybridizing with the A\(\alpha\) and A\(\beta\) probes are observed in the DNA of the two I-A\(^-\), I-E\(^+\) tumors, in comparison with control tissues. In addition, no hybridizing fragments are lost by any of the I-A\(^-\), I-E\(^+\) B10.A B cell tumors (data not shown). Southern blot analyses with the MuLV-specific AKV-LTR probe reveal that the DNA of both the MuLV-induced tumor 1189 and the spontaneous tumor 1464 contains a considerable number of integrated MuLV proviruses. DNA of individual transplants of these tumors contains an almost identical pattern of MuLV integrations in comparison with the primary tumor (data not shown).

Chromosome Analyses. To address the question whether the I-A\(^-\), I-E\(^+\) phenotype could be correlated with specific chromosomal aberration(s), chromosome
FIGURE 2. Expression of class II MHC-specific mRNA by B10.A B cell lymphomas. Northern blot analysis of 20 μg total cellular RNA on formaldehyde-treated 1.0% agarose gels was performed as described (27). Nitrocellulose filters were successively incubated with the Aα, Aβ, and Eβ specific hybridization probes, washed, and exposed to x-ray film. RNA was isolated from: lane 1, YAC, T cell line; lanes 2 and 3, two individual transplants of the I-A-, I-E + B10.A tumor 1189; lanes 4–6, three individual transplants of the I-A-, I-E + B10.A tumor 1464; lanes 7–9, three individual primary B10.A B cell tumors with I-A+, I-E+ phenotype.

spreads of I-A-, I-E+ transplants of both tumors were examined by the Giemsa banding technique.

Transplant of Tumor 1189. A total of 48 metaphases were analyzed, 37 from the spleen and 11 from the liver. All 27 cells with an XY constitution had an apparently normal male karyotype and were therefore considered as being derived from dividing host cells. Cells with an XX constitution represented the tumor cell population. The stem line consisted of the following karyotype: 39,XX,t(4;19),t(11;17),der(18)(15;18),−12,+mar 15 (Fig. 3). The breakpoints for the translocations were as follows: t(4;19)(E2;B), t(11;17)(E2;D), and der(18)(15;18)(A2;E3). The marker chromosome 15 had an insertion of unknown chromosome material in band A2.

Transplant of Tumor 1464. A total of 63 metaphases were examined, 35 from the spleen and 28 from a lymph node, all of which had an XX constitution and were therefore of tumor cell origin. The numerical range varied between 48 to 49 chromosomes per cell. 31 cells were karyotyped; all had +2, +3, +16, +17, +18, +19, and a translocation t(6;11)(D;A5). The majority of cells also had an extra chromosome 15 as a simple trisomy, with four instances of a tandem...
duplication. An additional number 18 was also present in 10 cells, and nearly all
metaphases had one or two small unidentifiable marker chromosomes.

Discussion

The minimal I-A^k expression on the cell surface of two B10.A B cell lymphomas
is most likely caused by a strongly reduced level of Aα- (tumor 1464) or Aβ-
tumor 1189) specific mRNA. We cannot exclude that some of the residual signal
of Aα or Aβ mRNA is caused by cross hybridization of the hybridization probes
used. Several mechanisms could account for these imbalances in Aα and Aβ mRNA expression.

First, soluble mediators (e.g., interferons, growth factors) may induce mRNA expression and cell surface expression of the I-A or I-E molecules selectively. This hypothesis is supported by the observation that, on human endothelial cells and dermal fibroblasts, recombinant human IFN-γ enhances the expression of HLA-DR more strongly than of HLA-DC antigens (48). In addition, in the human myelocytic leukemia cell line HL-60, IFN-γ induces the cell surface expression of DR but not of DC antigens (49). The induction by IFN-γ of DR antigens on HL-60 cells is associated with the induction of high level DRα and DRβ mRNA, without a simultaneous induction of DCα and DCβ mRNA expression (49). In organs of moribund mice, which almost exclusively contain malignant B cells, the relative scarcity of (T cell–dependent) mediators could account for the absence of I-A expression. In pilot experiments, however, we were unable to induce I-Ak expression in an in vitro cell line of the I-A−, I-E+ tumor 1464 by in vitro administration of recombinant mouse IFN-γ (data not shown).

Second, the I-A− tumors may contain altered promoter and/or enhancer regions of the Aα (tumor 1464) or Aβ gene (tumor 1189). Subtle nucleotide changes or small insertions/deletions in the Aα or Aβ genes may not be detected by the Southern blot analyses performed in this study. The existence of separate enhancer elements for class II MHC genes may be indicated by the differential tissue distribution and ontogeny of DC-I and HLA-DR antigens in man (50). Moreover, recently, a cell type–specific enhancer element associated with the mouse Eβ gene has been identified (51). Alteration of (a) transcriptional control site(s) may be related to the chromosomal aberrations involving chromosome 17 (trisomy or translocations) observed in both I-A− tumors, and may thereby influence the relative mRNA expression of the I-A and I-E genes. In this respect it is striking that one of the I-A−, I-E+ tumors contains a (11; 17) translocation with a breakpoint on chromosome 17 that is localized within or very close to the H-2 complex, which has been assigned to the 17C-E1 region of chromosome 17 (52). Although we have found no confirmation that this breakpoint maps within the I-A region itself, a region close to I-A could be involved. Otherwise, this I-A−, I-E+ tumor still possesses a cytogenetically normal chromosome 17. Hence, the (11; 17) translocation may represent an event independent from the loss of I-Ak expression, but associated with the induction of the malignant state of mouse B cell lymphomas with a less differentiated phenotype than murine plasmacytomas, which often contain a (12; 15) or (6; 15) translocation (53, 54). So far we have examined the karyotype of two additional B10.A B cell tumors (which possess an I-A+, I-E+ phenotype). In the karyotype of a transplant of the I-A+ tumor 1099 (Table III), trisomy of the chromosomes 11 and 15 was observed (data not shown). In a transplant of the I-A+, I-E+ B10.A tumor 1285 (Table III), a large number of chromosomal aberrations was present, including a t(3;9)(D;D) and two chromosomes 11 containing insertion of unknown chromosomal material (data not shown). Hence, in conclusion, the chromosomal aberrations present in the B10.A B cell lymphomas investigated thus far are rather heterogeneous. However, in all four B10.A B cell tumors examined, abnormalities in chromosomes 11 and 15 were observed, resembling the chro-
mosomal aberrations reported for plasmacytomas induced by mineral oil in combination with the Abelson-Moloney virus (54). This raises the possibility that in tumor 1189, as a result of the (11; 17) translocation, one of the cellular oncogenes on chromosome 11 (i.e. p53, erbA, erbB, or others) is brought under control of promoter and/or enhancer regions present within the H-2 complex.

Third, the B10.A B cell lymphomas may contain unaltered Aα and Aβ genes but express unknown tumor cell–associated cellular proteins that modify the level of Aα or Aβ mRNA. These unknown proteins could influence transcription of the Aα or Aβ gene through direct regulation of the activity of the promoter or enhancer regions of the genes involved. Alternatively, these proteins could influence the stability of Aα or Aβ mRNA. A direct role of a MuLV protein, in analogy with the adenovirus 12 E1A product (27, 28), seems unlikely, because a large number of MuLV-expressing murine B cell lymphomas show normal expression of I-A/E mRNA and antigens. However, the generation of a mutant/recombinant MuLV that encodes such a protein cannot be excluded.

Two murine B cell tumors were observed with strongly reduced cell surface I-A expression. Noteworthy, in another study, 3 out of 20 B cell non-Hodgkin's lymphomas in man were also shown to lack expression of DC antigens (the human analog of the mouse I-A antigen [55]), in spite of a high expression of DR and SB gene products (56). Perhaps an I-A−, I-E+ phenotype may be a normal phenomenon at some stage in the differentiation of mouse B cells, although to our knowledge such a population of B cells has not yet been reported. However, the observation that in one tumor a reduced Aα mRNA but in the other a reduced Aβ mRNA level was observed argues against this hypothesis. A more likely explanation for the minimal expression or lack of I-A antigen is immunoselection to escape from I-A-restricted immune surveillance in vivo. The frequency of aberrant I-A expression in primary B10.A B cell lymphomas (2 out of 24) is low. Although both I-A−, I-E+ tumors were transplantable in syngeneic mice, the overall transplantability frequency of B10.A B cell lymphomas does not allow any conclusion concerning a difference in transplantability of I-A−, I-E+ vs. I-A+, I-E+ tumors, if only because the frequency of testable I-A+, I-E+ tumors is too low. In addition, no selection towards an I-A−, I-E+ phenotype is apparent upon transplantation of I-A+, I-E+ tumors. However, this does not exclude the possibility that immunoselection against a class II MHC–restricted MuLV-specific T cell response may occur in some of the B cell lymphomas. In other individual tumors, immunoselection may involve loss of the viral target antigen rather than MHC molecules from the cell surface. Immunoselection in vivo by class I MHC–restricted Moloney MuLV–specific CTL leading to the loss of the viral target antigen was recently documented by van der Hoorn et al. (57). The ultimate answer of whether the I-A−, I-E+ phenotype of tumors 1189 and 1464 has biological significance has to come from transfection and expression of cloned Aα and Aβ genes in these tumors, followed by study of the comparative transplantability of transfected vs. untransfected tumor lines.

Summary
To study the role of class II MHC expression in mouse lymphomagenesis, we examined the cell surface expression of I-A/E antigens on 24 spontaneous or
murine leukemia virus (MuLV)-induced mouse B10.A (I-A^k, I-E^k) B cell lymphomas. Two primary B10.A B cell lymphomas were observed with strong I-E^k expression but with only minimal cell surface I-A^k expression. Both tumors are readily transplantable in syngeneic mice, with maintenance of their I-A^k, I-E^k phenotype. Strikingly, one I-A^k, I-E^k B cell lymphoma contains a (11; 17) translocation with a breakpoint on chromosome 17 that is localized within or very close to the H-2 complex. DNA of both tumors contains normal restriction enzyme fragments of the Aα and Aβ genes. Northern blot analyses indicated that one I-A^-, I-E^+ tumor strongly expressed Aα, Eα, and Eβ mRNAs but possessed only a weak expression of Aβ mRNA. The other B cell lymphoma showed Aβ, Eα, and Eβ mRNA expression but only minimal Aα mRNA expression. In 11 primary B10.A B cell lymphomas with a normal I-A^+, I-E^+ phenotype, no imbalances in Aα/Aβ mRNA levels were observed. The implications of these findings for the role of class II MHC expression in mouse B cell lymphomagenesis are discussed.

We thank Dr. R. N. Germain for providing the class II MHC-specific hybridization probes, Dr. G. J. Hämmerling for providing the I-A/E-specific mAb, Dr. T. Radaszkiewicz for the morphological characterization of the tumor cells, Dr. G. Levan (Department of Genetics, University of Göteborg) for his assistance in the chromosomal analysis, and our colleagues for helpful discussions.

Received for publication 15 August 1985 and in revised form 30 January 1986.

References
1. Lilly, F., and T. Pincus. 1973. Genetic control of murine viral leukemogenesis. Adv. Cancer Res. 17:231.
2. Meruelo, D., M. Lieberman, N. Ginzton, B. Deak, and H. O. McDevitt. 1977. Genetic control of radiation leukemia virus-induced tumorigenesis. I. Role of the major murine histocompatibility complex, H-2. J. Exp. Med. 146:1079.
3. Chesebro, B., and K. Wehrly. 1978. Rfv-1 and Rfv-2, two H-2-associated genes that influence recovery from Friend leukemia virus-induced splenomegaly. J. Immunol. 120:1081.
4. Debre, P., S. Gisselbrecht, F. Pozo, and J. P. Levy. 1979. Genetic control of sensitivity to Moloney leukemia virus in mice. II. Mapping of three resistant genes within the H-2 complex. J. Immunol. 123:1806.
5. Lonai, P., and N. Haran-Ghera. 1980. Genetic resistance to murine leukemia induced by different radiation leukemia virus variants; a comparative study on the role of the H-2 complex. Immunogenetics. 11:21.
6. Melief, C. J. M., A. Vlug, R. E. Y. de Goede, C. de Bruyne, W. Barendsen, and P. de Greeve. 1980. Naturally occurring leukemia viruses in H-2 congenic C57BL mice. I. High lymphoma incidence following milk-borne transmission of virus. J. Natl. Cancer Inst. 64:1179.
7. Zijlstra, M., R. E. Y. de Goede, H. Schoenmakers, T. Radaszkiewicz, and C. J. M. Melief. 1984. Ecotropic and dualtropic MCF murine leukemia viruses can induce a wide spectrum of H-2-controlled lymphoma types. Virology. 138:198.
8. Lonai, P., E. Katz, and N. Haran-Ghera. 1980. 1-region linked complementating loci in resistance to viral leukemogenesis in the mouse. Immunogenetics. 10:535.
9. Meruelo, D., S. Nimelstein, P. Jones, M. Lieberman, and H. O. McDevitt. 1978. Increased synthesis and expression of H-2 antigens as a result of radiation leukemia
virus infection. A possible mechanism for H-2 linked control of virus-induced neoplasia. *J. Exp. Med.* 147:470.

10. Meruelo, D. 1979. A role for elevated H-2 antigen expression in resistance to neoplasia caused by radiation-induced leukemia virus. Enhancement of effective tumor surveillance by killer lymphocytes. *J. Exp. Med.* 149:898.

11. Debré, P., B. Boyer, S. Gisselbrecht, A. Bismuth, and J. P. Levy. 1980. Genetic control of sensitivity to Moloney leukemia virus in mice. III. The three H-2-linked Rmv genes are immune response genes controlling the antiviral antibody response. *Eur. J. Immunol.* 10:914.

12. Britt, W. J., and B. Chesebro. 1983. H-2D control of recovery from Friend virus leukemia: H-2D region influences the kinetics of the T lymphocyte response to Friend virus. *J. Exp. Med.* 157:1736.

13. Lonai, P., E. Katz, and N. Haran-Ohera. 1982. Role of the major histocompatibility complex in resistance to viral leukaemia; its effect on the preleukemic stage of leukemogenesis. *Springer Semin. Immunopath.* 4:373.

14. Vlug, A., C. J. M. Melief, C. de Bruyne, H. Schoenmakers, and J. L. Molenaar. 1980. Naturally occurring leukemia viruses in H-2 congenic C57BL mice. II. Antibody response to viral envelope antigens. *J. Natl. Cancer Inst.* 64:1191.

15. Vlug, A., H. J. Schoenmakers, and C. J. M. Melief. 1981. Genes of the H-2 complex regulate the antibody response to murine leukemia virus. *J. Immunol.* 126:2355.

16. Vlug, A., M. Zijlstra, R. E. Y. de Goede, W. G. Hesselink, H. J. Schoenmakers, and C. J. M. Melief. 1983. H-2 control of the cytotoxic antibody response against a newly defined MuLV-related cell-surface antigen:G(B10.A). *Int. J. Cancer* 31:617.

17. Festenstein, H., and W. Schmidt. 1981. Variation in MHC antigenic profiles of tumor cells and its biological effects. *Immunol. Rev.* 60:85.

18. Hui, K., F. Grosveld, and H. Festenstein. 1984. Rejection of transplantable AKR leukemia cells following MHC DNA-mediated cell transformation. *Nature (Lond.)* 311:790.

19. Baldacci, P., F. Pozo, S. Gisselbrecht, and Ph. Kourilsky. 1985. Altered transcription of genes coding for class I histocompatibility antigens in murine tumor cells. *J. Exp. Med.* 158:1294.

20. Rosloniec, E. F., M. H. Kuhn, C. A. Genyca, A. H. Reed, J. J. Jennings, A. A. Giraldo, K. W. Beisel, and S. P. Lerman. 1984. Agressiveness of SJL/J lymphomas correlates with the absence of H-2D' antigens. *J. Immunol.* 132:945.

21. Eisenbach, L., S. Segal, and M. Feldman. 1983. MHC imbalance and metastatic spread in Lewis lung carcinoma clones. *Int. J. Cancer* 32:113.

22. De Baetselier, P., S. Katzav, E. Gorelik, M. Feldman, and S. Segal. 1980. Differential expression of H-2 gene products in tumour cells is associated with their metastaticogenic properties. *Nature (Lond.)* 288:179.

23. Katzav, S., S. Segal, and M. Feldman. 1984. Immuno-selection in vivo of H-2D phenotypic variants from a metastatic clone of sarcoma cells results in cell lines of altered metastatic competence. *Int. J. Cancer* 35:407.

24. Gooding, L. R. 1982. Characterization of a progressive tumor from C3H fibroblast transformed in vitro with SV40 virus. Immunoresistance in vivo correlates with phenotypic loss of H-2K'4. *J. Immunol.* 129:1506.

25. Wallich, R., N. Bulbuc, G. J. Hämmerling, S. Katzav, S. Segal, and M. Feldman. 1985. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. *Nature (Lond.)* 315:301.

26. Baniyash, M., N. Smorodinsky, M. Voakubovicz, and I. Witz. 1982. Serologically detectable MHC and tumor-associated antigens on B16 melanoma variants and humoral immunity in mice bearing these tumors. *J. Immunol.* 129:1293.
27. Schrier, P. I., R. Bernards, R. T. M. J. Vaessen, A. Houweling, and A. J. van der Eb. 1983. Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. *Nature (Lond.)*. 305:771.

28. Bernards, R., P. I. Schrier, A. Houweling, J. L. Bos, A. J. van der Eb, M. Zijlstra, and C. J. M. Melief. 1983. Tumorigenicity of cells transformed by adenovirus type 12 by evasion of T-cell immunity. *Nature (Lond.)*. 305:776.

29. Tanaka, K., K. J. Isselbacher, G. Khoury, and G. Jay. 1985. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. *Science (Wash. DC)*. 228:26.

30. Zijlstra, M., R. E. Y. de Goede, H. J. Schoenmakers, A. H. Schinkel, W. G. Hesselink, J. L. Portis, and C. J. M. Melief. 1983. Naturally occurring leukemia viruses in H-2 congeneric C57BL mice. III. Characterization of C-type viruses isolated from lymphomas induced by milk transmission of B-ecotropic virus. *Virology*. 125:47.

31. Pattengale, P. K., and C. R. Taylor. 1983. Experimental models of lymphoproliferative disease. The mouse as a model for human non-Hodgkins lymphomas and related leukemias. *Am. J. Pathol.* 113:237.

32. Ledbetter, J. A., and L. A. Herzenberg. 1979. Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. *Immunol. Rev.* 47:63.

33. Coffman, R. L., and L. L. Weissman. 1981. A monoclonal antibody that recognizes B cells and B-cell precursors in mice. *J. Exp. Med.* 153:269.

34. Trowbridge, I. S., and M. B. Omary. Molecular complexity of leucocyte surface glycoproteins related to the macrophage differentiation antigen mac-1. *J. Exp. Med.* 154:1517.

35. Lemke, H., G. J. Hämmerling, and U. Hämmerling. 1979. Fine specificity analysis with monoclonal antibodies of antigens controlled by the major histocompatibility complex and by the Qa/TL region in mice. *Immunol. Rev.* 47:175.

36. Ozato, K., and D. H. Sachs. 1981. Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression. *J. Immunol.* 126:317.

37. Ozato, K., N. M. Mayer, and D. H. Sachs. 1982. Monoclonal antibodies to mouse major histocompatibility complex antigens. IV. A series of hybridoma clones producing anti-H-2b antibodies and an examination of expression of H-2d antigens on the surface of these cells. *Transplantation (Baltimore)*. 34:113.

38. Oi, V. T., P. P. Jones, J. W. Goding, L. A. Herzenberg, and L. A. Herzenberg. 1978. Properties of monoclonal antibodies to mouse Ig allotypes, H-2 and Ia antigens. *Curr. Top. Microbiol. Immunol.* 81:115.

39. Ozato, K., N. Mayer, and D. H. Sachs. 1980. Hybridoma cell lines secreting monoclonal antibodies to mouse Ig allotypes, H-2 and Ia antigens. *J. Immunol.* 124:533.

40. Nusse, R., and H. E. Varmus. 1982. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. *Cell.* 31:99.

41. Quint, W., W. Quax, H. van der Putten, and A. Berns. 1981. Characterization of AKR murine leukemia virus sequences in AKR mouse substrains and structure of integrated recombinant genomes in tumor tissues. *J. Virol.* 39:1.

42. Muller, R., D. J. Slamon, J. M. Tremblay, M. J. Cline, and I. M. Verma. 1982. Differential expression of cellular oncogenes during pre- and postnatal development of the mouse. *Nature (Lond.)*. 299:640.

43. Quint, W., W. Boelens, P. van Wezenbeek, Th. Cuypers, E. R. Maandag, G. Selten, and A. Berns. 1984. Generation of AKR mink-cell focus-forming viruses: a conserved single copy xenotropic-like provirus provides recombinant long terminal repeat sequences. *J. Virol.* 50:432.
44. Germain, R. N., J. D. Ashwell, R. I. Lechler, D. H. Margulies, K. M. Nickerson, G. Suzuki, and J. Y. L. Tou. 1985. "Exon-shuffling" maps control of antibody- and T-cell-recognition sites to the NH₂-terminal domain of the class II major histocompatibility polypeptide Aβ. Proc. Natl. Acad. Sci. USA. 82:2940.

45. Robinson, R. R., R. N. Germain, D. J. McKean, M. Mescher, and J. G. Seidman. 1983. Extensive polymorphism surrounding the murine Ia Aβ chain gene. J. Immunol. 131:2025.

46. Herbst, E. W., A. Gropp, and C. Tietgen. 1981. Chromosome rearrangements involved in the origin of trisomy 15 in spontaneous leukemia of AKR mice. Int. J. Cancer. 28:805.

47. Committee on standard genetic nomenclature for mice 1972. Standard karyotype of the mouse, Mus musculus. J. Hered. 63:69.

48. Collins, T., A. J. Korman, C. T. Wake, J. M. Boss, D. J. Kappes, W. Fiers, K. A. Ault, M. A. Gimbrone, Jr., J. L. Strominger, and J. S. Pober. 1984. Immune interferon activate multiple class II major histocompatibility complex genes and the associated invariant chain genes in human endothelial cells and dermal fibroblasts. Proc. Natl. Acad. Sci. USA. 81:4917.

49. Koeffler, H. P., J. Ranyard, L. Yelton, R. Billing, and R. Bohman. 1984. γ-interferon induces expression of the HLA-D antigens on normal and leukemic human myeloid cells. Proc. Natl. Acad. Sci. USA. 81:4080.

50. Natali, P. G., O. Segatto, S. Ferrone, R. Tosi, and G. Corte. 1984. Differential tissue distribution and ontogeny of DC-1 and HLA-DR antigens. Immunogenet. 19:109.

51. Gillies, S. D., V. Folsom, and S. Tonegawa. 1984. Cell type-specific enhancer element associated with a mouse MHC gene, Eβ. Nature (Lond.). 310:594.

52. Klein, J., F. Figueroa, and D. Klein. 1982. H-2 haplotypes, genes, and antigens: second listing. I. Non-H-2 loci on chromosome 17. Immunogenet. 16:285.

53. Klein, G. 1983. Specific chromosomal translocations and the genesis of B cell-derived tumors in mice and men. Cell. 32:311.

54. Ohno, S., S. Migita, F. Wiener, M. Babonits, G. Klein, J. F. Mushinski, and M. Potter. 1984. Chromosomal translocations activating myc sequences and transduction of v-abl are critical events in the rapid induction of plasmacytomas by pristane and Abelson virus. J. Exp. Med. 159:1762.

55. Bono, M. R., and J. L. Strominger. 1982. Direct evidence of homology between human DC-1 antigen and murine I-A molecules. Nature (Lond.). 299:836.

56. Krajewski, A. S., A. E. Dewar, and D. Cossar. 1985. Immunohistochemical analysis of human MHC class II antigens in B-cell non-Hodgkin's lymphomas. J. Pathol. 145:185.

57. Van der Hoorn, F. A., T. Lahaye, V. Müller, M. A. Ogle, and H. D. Engers. 1985. Characterization of gp85<sup>PE</sup> as an antigen recognized by Moloney leukemia virus-specific cytotoxic T cell clones that function in vivo. J. Exp. Med. 162:128.